Navigating 2025 Drug Pricing Policies webinar, panelists discussed the Most Favored Nation executive order, bills aimed at ...

Food and Drug Administration Commissioner Marty Makary said his agency may fast-track new drugs from pharmaceutical companies that “equalize” the cost of their medicines between the US and other ...

There's little point in pouring hundreds of millions of dollars into creating a biosimilar if PBMs will refuse to cover it.

Merck on Wednesday appeared to take a step towards addressing the looming Keytruda patent cliff. The company is closing in on ...